Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

3
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Agewall S. New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials. Eur Heart J Cardiovasc Pharmacother 2022;8:213-215. [PMID: 35435962 DOI: 10.1093/ehjcvp/pvac019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 03/16/2022] [Indexed: 06/14/2023]

For:	Agewall S. New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials. Eur Heart J Cardiovasc Pharmacother 2022;8:213-215. [PMID: 35435962 DOI: 10.1093/ehjcvp/pvac019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 03/16/2022] [Indexed: 06/14/2023]

Number

Cited by Other Article(s)

Agewall S. The search for the perfect antiplatelet treatment continues. EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY 2023;9:671-672. [PMID: 38093457 DOI: 10.1093/ehjcvp/pvad079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 10/23/2023] [Indexed: 12/18/2023]

Agewall S. Cardiovascular preventive actions. EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY 2023;9:497-498. [PMID: 37727121 DOI: 10.1093/ehjcvp/pvad054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 07/28/2023] [Indexed: 09/21/2023]

Agewall S. Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that? EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY 2023;9:401-402. [PMID: 37486237 DOI: 10.1093/ehjcvp/pvad049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 06/29/2023] [Indexed: 07/25/2023]